Potential claims generally involve medications containing the active ingredient semaglutide or tirzepatide, including Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound
In the SURMOUT-1 trial 2,539 patients underwent randomization to tirzepatide or placebo and were followed for 72 weeks demonstrating up to 20.9% weight reduction with maintenance dosing versus 3.1% in the placebo group for a net 17.8% weight reduction [35]
Taking time to understand each step ensures you get the most from your medication
And if foods arent perceived by the brain as tasty, then it makes sense that people would crave them less, and consume less of them, she explains
o AstraZeneca PLC o Roche Holding AG o Zealand Pharma A/S o Hanmi Pharmaceutical Co., Ltd
What are the potential side effects of GLP-1s